- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Silexion Therapeutics Corp - S-1/A, General form for registration of securities | 1 | SEC Filings | ||
| Mo | Silexion Therapeutics Corp - 8-K, Current Report | 2 | SEC Filings | ||
| SILEXION THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| Fr | Silexion Therapeutics Corp - S-1, General form for registration of securities | 1 | SEC Filings | ||
| 04.08. | Silexion präsentiert präklinische Daten zu Krebsmedikament SIL-204 auf Symposium für GI-Tumoren | 2 | Investing.com Deutsch | ||
| 04.08. | Silexion to present preclinical data on SIL-204 at GI cancer event | 1 | Investing.com | ||
| 04.08. | Silexion Therapeutics Corp: Silexion Therapeutics Reports New Positive Preclinical Findings Demonstrating Multi-Mechanism Immune Sensitization by SIL204 in KRAS-Driven Cancers | 325 | GlobeNewswire (Europe) | New preclinical data demonstrate that SIL204 treatment produced statistically significant upregulation of FAS (CD95), the immune "death receptor," and statistically significant downregulation of HLA-G... ► Artikel lesen | |
| 29.07. | Silexion Therapeutics Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 21.07. | Silexion Therapeutics Corp - 8-K, Current Report | 2 | SEC Filings | ||
| 23.06. | Silexion Therapeutics Corp: Silexion Therapeutics Receives Approval from Germany's BfArM to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer | 433 | GlobeNewswire (Europe) | CTA Approval from Germany's Federal Institute for Drugs and Medical Devices (BfArM), accompanied by a positive opinion from the Ethics Committee of the North Rhine Medical Association, clears Silexion... ► Artikel lesen | |
| 16.06. | Silexion Therapeutics Corp: Silexion Therapeutics to Attend BIO International Convention 2026 | 1 | GlobeNewswire (USA) | ||
| 28.05. | Silexion Therapeutics Corp - S-8, Securities to be offered to employees in employee benefit plans | 14 | SEC Filings | ||
| 26.05. | Silexion Therapeutics announces 1-for-10 reverse share split | 1 | Seeking Alpha | ||
| 26.05. | Silexion announces 1-for-10 reverse stock split effective Thursday | 1 | Investing.com | ||
| 26.05. | Silexion Therapeutics Corp - 8-K, Current Report | 2 | SEC Filings | ||
| 26.05. | Silexion: Aktienzusammenlegung im Verhältnis 1 zu 10 wird am Donnerstag wirksam | 3 | Investing.com Deutsch | ||
| 26.05. | Silexion Therapeutics Corp: Silexion Therapeutics Announces 1-for-10 Reverse Share Split | 371 | GlobeNewswire (Europe) | Grand Cayman, May 26, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies... ► Artikel lesen | |
| 19.05. | Silexion Therapeutics Corp - 10-K/A, Annual Report | 2 | SEC Filings | ||
| 18.05. | Silexion Therapeutics GAAP EPS of -$0.85 beats by $0.44 | 1 | Seeking Alpha | ||
| 18.05. | Silexion Therapeutics Corp: Silexion Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update | 453 | GlobeNewswire (Europe) | Israeli Ministry of Health approved the initiation of Silexion's Phase 2/3 clinical trial of SIL204 in locally advanced pancreatic cancer Clinical Trial Application subsequently submitted to Germany... ► Artikel lesen | |
| 15.05. | Silexion Therapeutics Corp - 10-Q, Quarterly Report | 1 | SEC Filings |
1 2 3 Weiter >>
45 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 80,00 | -1,23 % | Ihre wichtigsten Termine: Q2-Updates von SpaceX, Bayer, Biontech, Spotify, Pfizer, Continental, Merck & Co | © Foto: Dall-EGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Untermehmenstermine 05:00 Uhr, Großbritannien:... ► Artikel lesen | |
| AMGEN | 358,80 | -0,72 % | Guggenheim raises Amgen stock price target to $388 on strong quarter | ||
| NOVAVAX | 6,870 | +0,59 % | Novavax, Inc.: Novavax Reports Second Quarter 2026 Financial Results and Operational Highlights | Reported total revenue of $57 million for the second quarter of 2026 and raised full-year 2026 Revenue Framework
Improved GAAP Combined R&D and SG&A expense... ► Artikel lesen | |
| BIOGEN | 177,40 | -1,19 % | Biogen Inc.: Biogen Completes Acquisition of RayThera Inc. | Lead program now in Phase 1 developmentCAMBRIDGE, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the completion of the acquisition of RayThera Inc., a privately... ► Artikel lesen | |
| VIKING THERAPEUTICS | 29,600 | -0,84 % | Better GLP-1 Stock to Buy: Eli Lilly or Viking Therapeutics? | ||
| INTELLIA THERAPEUTICS | 10,320 | -0,96 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates | Positive Phase 3 HAELO clinical data for lonvo-z in HAE presented at EAACI and published in New England Journal of MedicineAnticipate FDA acceptance of BLA for lonvo-z in second half of 2026 and U.S.... ► Artikel lesen | |
| TEMPUS AI | 47,680 | -0,04 % | Opening Bell: Wall Street auf Erholungskurs; Alphabet, SpaceX, Intel, Tempus AI, NextEra Energy ... | Die US-Börsen wagen am Freitag wohl einen Stabilisierungsversuch nach dem erneuten Rückschlag am Vortag. Besonders galt dies für den Leitindex Dow Jones Industrial, der eine Stunde vor dem Auftakt vom... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 9,108 | +6,68 % | Biocryst outlines $690M-$715M 2026 total revenue guidance with operating costs at $420M-$440M | ||
| BIOMARIN PHARMACEUTICAL | 60,50 | +1,34 % | BioMarin Pharmaceutical Inc.: BioMarin Reports Second Quarter 2026 Financial and Operating Results | Second Quarter 2026 Total Revenues Increased 20% Year-over-year to $990 million
Stronger Growth Expectations Drive Increased Guidance for Full-year 2026 Total Revenues... ► Artikel lesen | |
| EXELIXIS | 46,080 | +0,39 % | Exelixis outlines zanza CRC launch plans as 2026 revenue guidance midpoint is lowered by $50M | ||
| SAREPTA THERAPEUTICS | 15,460 | +3,76 % | Sarepta's Q2 Earnings & Sales Beat Estimates, '26 Outlook Updated | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,018 | +2,57 % | PacBio Announces Second Quarter 2026 Financial Results | MENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended June 30, 2026. Recent Business Highlights Total revenue of $39.0... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 1,266 | +0,48 % | Cardiol Therapeutics bei Canaccord Genuity: Phase-III-Katalysator rückt näher | ||
| VAXART | 0,600 | 0,00 % | Vaxart outlines Phase IIb COVID-19 top line data in first half of 2027 backed by BARDA funding | ||
| ATAIBECKLEY | 6,250 | -0,79 % | Warum Lillys 3,8-Milliarden-Dollar-Deal den Psychedelika-Sektor verändert - und warum Emyria jetzt in den Fokus rücken könnte |
Das Unternehmen SILEXION THERAPEUTICS CORP kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 1,260 Euro und damit -16,00 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SILEXION THERAPEUTICS CORP finden Sie auf Wallstreet Online.